selegiline has been researched along with benserazide in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (64.52) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rinne, UK | 1 |
| Birkmayer, W | 2 |
| Rinne, UK; Siirtola, T; Sonninen, V | 1 |
| Dettner, O; Gerlach, M; Kuhn, W; Przuntek, H; Russ, H | 1 |
| Kraus, P; Kuhn, W; Przuntek, H | 1 |
| Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A | 1 |
| Stern, G | 1 |
| Birkmayer, GD; Birkmayer, W | 1 |
| Csanda, E; Takáts, A; Tárczy, M | 1 |
| Birkmayer, JD; Birkmayer, W | 1 |
| Yahr, MD | 1 |
| Kuhn, W; Przuntek, H | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Birkmayer, W; Hars, V; Knoll, J; Marton, J; Riederer, P; Youdim, MB | 1 |
| Baraczka, K; Fekete, MI; Kanyicska, B | 1 |
| Csanda, E; Katona, G; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Csanda, E; Tárczy, M | 1 |
| Gerstenbrand, F; Poewe, W; Ransmayr, G | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T | 1 |
| Dichgans, J; Klockgether, T | 1 |
| Lees, AJ | 1 |
| Shan, DE; Yeh, SI | 1 |
| Ahtila, S; Kaakkola, S; Lyytinen, J; Teräväinen, H; Tuomainen, P | 1 |
| Hagell, P; Odin, P; Vinge, E | 1 |
| Munhoz, RP; Teive, HA; Zavala, JA | 1 |
| Almeida, KJ; Campos Sousa, RN; de Oliveira Filho, MC; Guimarães Silva, JS; Lopes Nery, PC | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
4 review(s) available for selegiline and benserazide
| Article | Year |
|---|---|
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism | 1987 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline | 1998 |
5 trial(s) available for selegiline and benserazide
| Article | Year |
|---|---|
The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Topics: Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Visual control of arm movement in Parkinson's disease.
Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline | 1994 |
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Selegiline; Time Factors; Treatment Failure | 1995 |
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Topics: Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline; Single-Blind Method | 1996 |
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Nitriles; Parkinson Disease; Selegiline | 1997 |
22 other study(ies) available for selegiline and benserazide
| Article | Year |
|---|---|
Long term treatment with L-deprenyl.
Topics: Benserazide; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1978 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid | 1978 |
(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity.
Topics: Aged; Benserazide; Catechol O-Methyltransferase; Erythrocytes; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline | 1991 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
MPTP: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Pyridines; Selegiline | 1986 |
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Topics: Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Retrospective Studies; Selegiline; Time Factors | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1987 |
Deprenyl in Parkinson disease: personal experience.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
Topics: Adult; Aged; Benserazide; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Life Expectancy; Longitudinal Studies; Male; Middle Aged; Models, Biological; Phenethylamines; Retrospective Studies; Selegiline | 1985 |
Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase; Phenethylamines; Phenylacetates; Selegiline | 1983 |
L-deprenyl in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
[Bromocriptine-induced pleuropneumopathy].
Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion; Pulmonary Atelectasis; Pulmonary Fibrosis; Radiography; Selegiline; Time Factors | 1994 |
Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
Topics: Ankle; Antiparkinson Agents; Benserazide; Benzothiazoles; Drug Therapy, Combination; Edema; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline | 2012 |
Zoophilia and Parkinson's disease.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sexual Dysfunctions, Psychological | 2013 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |